Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 11, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).

D Binda1, E K Vanhoutte, G Cavaletti

  • 1Department of Surgery and Translational Medicine, University of Milan-Bicocca, Monza, Italy.

European Journal of Cancer (Oxford, England : 1990)
|May 15, 2013
PubMed

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair/microsatellite unstable metastatic colorectal cancer": [ESMO Gastrointestinal Oncology, Volume 5, 100069].

ESMO gastrointestinal oncology·2026
Same author

The role of the molecular tumor board: learnings from the ROME trial.

NPJ precision oncology·2026
Same author

Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair/microsatellite unstable metastatic colorectal cancer.

ESMO gastrointestinal oncology·2026
Same author

Brain Microstructural Damage as Potential Biomarker of Immune Cell-Associated Neurotoxicity Syndrome.

Journal of neuroimaging : official journal of the American Society of Neuroimaging·2026
Same author

NfL as a biomarker in ATTRv amyloidosis: potential and limitations.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2025
Same author

Assessing Hand Function in Trans-Radial Amputees Wearing Myoelectric Hands: The Virtual Eggs Test (VET).

IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society·2025
Summary

Researchers developed a new 28-item scale to measure disability in chemotherapy-induced peripheral neuropathy (CIPN) patients. This validated tool, the CIPN-R-ODS, accurately assesses activity limitations and participation restrictions, improving CIPN patient care.

Area of Science:

  • Neurology
  • Oncology
  • Psychometrics

Background:

  • Chemotherapy-induced peripheral neuropathy (CIPN) significantly impacts cancer patients' daily functioning and quality of life.
  • Current outcome measures for CIPN disability lack modern clinimetric evaluation.
  • There is a need for reliable and valid tools to assess activity limitations and participation restrictions in CIPN.

Purpose of the Study:

  • To develop an interval-weighted scale using Rasch methodology to capture activity limitations and participation restrictions in CIPN patients.
  • To determine the validity and reliability properties of the developed scale.
  • To create a disease-specific measure for disability in CIPN.

Main Methods:

  • A preliminary 146-item Rasch-built Overall Disability Scale (pre-R-ODS) was administered twice to 281 CIPN patients.
Keywords:
ChemotherapyDisability evaluationPatient questionnairePeripheral neuropathy

Related Experiment Videos

Last Updated: May 11, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

  • Rasch analyses were performed to assess model fit, with iterative item removal for misfits.
  • External validity was established by correlating the final scale with NCI-CTC neuropathy scales and the PI-NRS.

    • Main Results:

    • The initial scale required adaptation; items with misfit statistics, disordered thresholds, item bias, or local dependency were removed.
    • The final 28-item CIPN-R-ODS demonstrated unidimensionality and met Rasch model expectations.
    • The final CIPN-R-ODS exhibited proper validity and reliability, outperforming classical test theory ordinal measures.

    Conclusions:

    • The final CIPN-R-ODS is a valid and reliable Rasch-built, disease-specific, interval measure for assessing disability in CIPN patients.
    • This new scale addresses the limitations of existing ordinal-based measures.
    • The CIPN-R-ODS is recommended for use in future clinical trials evaluating CIPN.